# A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Study · id `cardio:ct-nct05261126` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05261126](<https://clinicaltrials.gov/study/NCT05261126>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05261126

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 381 participants.

## Technical summary

Registry record NCT05261126. Randomized; double masking; primary purpose treatment. Start 2022-03-10 (actual); primary completion 2022-11-28 (actual). Results posted on 2023-12-06.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 381 participants (enrolled count; ClinicalTrials.gov record NCT05261126, source copy `cardio:ctgov-nct05261126-2024-12-09`, retrieved 2026-10-31)
- Started: 2022-03-10 (actual) (ClinicalTrials.gov record NCT05261126, source copy `cardio:ctgov-nct05261126-2024-12-09`, retrieved 2026-10-31)
- Primary completion: 2022-11-28 (actual) (ClinicalTrials.gov record NCT05261126, source copy `cardio:ctgov-nct05261126-2024-12-09`, retrieved 2026-10-31)
- Completion: 2022-11-28 (actual) (ClinicalTrials.gov record NCT05261126, source copy `cardio:ctgov-nct05261126-2024-12-09`, retrieved 2026-10-31)
- Results first posted: 2023-12-06 (ClinicalTrials.gov record NCT05261126, source copy `cardio:ctgov-nct05261126-2024-12-09`, retrieved 2026-10-31)
- Countries: United States; Germany; Japan; Mexico; Norway; South Korea; Türkiye; United Kingdom (ClinicalTrials.gov record NCT05261126, source copy `cardio:ctgov-nct05261126-2024-12-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05261126-2024-12-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
- Condition: Hypercholesterolemia
- Condition: Familial Hypercholesterolemia
- Intervention (Drug): Enclitide Chloride
- Intervention (Drug): Placebo
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 (`cardio:pubmed-36889610`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2fea1ccc43e35ded95aa6ec2a2e4299e25a659f7e9837a5b317fcfa893f26296
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
